ClinicalTrials.gg
RecruitingNCT07634679B-FINDUpdated Oct 7, 2026

Impact of a Bladder Flap on Cesarean Scar Niche Development

An interventional study of Bladder flap formation in Cesarean Scar Defect, sponsored by Montefiore Medical Center. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 7, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 199 studies in Cicatrix with a site in United States — 25 open to participants now, 35 under way, 2 of them phase 3. Cicatrix · United States.

Planned enrollment
4th of 185
338 · median 25
Started
2026
with 5 others
No phase
131 of 199
17 open now
Primary completion
2027-09
later than 20 of 34 live
Registered
196th of 199
by date

Among the 199 studies in Cicatrix with a site in United States, this one is the 4th largest by planned enrollment of the 185 interventional ones that give a count, is one of 6 that started in 2026, is one of 131 with no phase, reaches primary completion later than 20 of the 34 other live ones, and was the 196th registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

25 of the 199 studies in Cicatrix with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Cicatrix with a site in United States, or all of them as a file.
02

Study summary

The goal of this trial is to examine if the completion or omission of a bladder flap impacts the location and formation of cesarean scar niche in women undergoing primary cesarean section. The main question it aims to answer is if omission of a bladder flap changes the prevalence of cesarean scar niche on a 6-8 week postpartum ultrasound. Researchers will compare participants that have a bladder flap made to those that have a bladder flap omitted at time of their primary cesarean delivery. Participants will have routine postpartum care and be asked to return for a 6-8 week postpartum transvaginal ultrasound.

Read the detailed description

As the rate of cesarean deliveries increases globally, the importance of a cesarean scar niche (CSN) has evolved into a significant clinical concern with long term obstetric and gynecologic implications including increasing risk for placenta accreta spectrum (PAS) in future pregnancies and abnormal uterine bleeding. In fact, the main cause of PAS is placentation into uterine scars secondary to cesarean deliveries

Bladder flap formation is a standard step in cesarean deliveries and involves dissecting the bladder off the uterus to push it inferiorly to allow better access to the lower uterine segment for hysterotomy and decrease risk of bladder injury. The lower uterine segment is targeted for hysterotomy as it has been shown that the proportion of muscle tissue and the thickness of the wall of the uterus increases as one travels from the cervix to the fundus. Therefore, by making an incision in the lower uterine segment, the surgeon has less tissue to go through to deliver the fetus and disrupts less muscle to preserve uterine myometrial integrity. While studies have suggested bladder flap omission in primary cesarean deliveries does not increase intraoperative complications and reduces operating time. CSN assessment was not an outcome evaluated in these studies and the decision to omit or perform a bladder flap is at the discretion of the surgeon.

Previous studies have looked at different surgical techniques and different cervical dilations at time of cesarean delivery and the impact on niche formation and location. There has been no consensus on hysterotomy or other surgical techniques to decrease risk of CSN formation. To our knowledge, there have not been studies that have assessed postoperative CSN in relation to completion or omission of a bladder flap prior to hysterotomy. As such, the investigator team hypothesizes that omission of a bladder flap lends itself to a more cephalad hysterotomy and potentially more clinically significant CSNs.

03

Conditions studied

  • Cesarean Scar Defect

Browse trials for

Keywords

  • Isthmocele
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Primary low transverse cesarean section performed at Montefiore Weiler or Wakefield Hospitals
  • Able to provide in English or Spanish
  • Plan for postpartum care at Montefiore Medical Center

Exclusion criteria

Exclusion Criteria:

  • History of a prior uterine surgery
  • Known congenital uterine anomalies
  • Inability to safely access lower uterine segment at time of delivery
  • Hysterotomy is extended past/outside the lower uterine segment at time of surgery
  • Hysterectomy is indicated prior to postpartum follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
338 participants (estimated)

Study arms

  • No intervention
    Bladder flap omission

    Participants randomized to this arm will have the bladder flap step omitted prior to low transverse hysterotomy formation. Participants will not need to alter their postoperative or postpartum care.

  • Experimental
    Bladder flap formation

    Participants randomized to this arm will have a bladder flap formed using standard procedure during the cesarean delivery prior to low transverse hysterotomy and delivery of the infant. As with the 'Bladder flap omission' arm, participants will not need to alter their postoperative or postpartum care.

    Procedure: Bladder flap formation

Interventions

  • ProcedureBladder flap formation

    Participants in this arm will have a bladder flap completed at the time of their cesarean delivery.

06

What researchers measure

Primary outcomes

  1. Presence of cesarean scar niche

    A dichotomous measure of the presence or absence of a cesarean scar niche, as defined by a residual myometrial thickness of \<3mm at the scar level, detected on transvaginal ultrasound. The presence of a cesarean scar niche increases risk for gynecologic complaints and abnormal placentation in subsequent pregnancies.

    Time frame: From enrollment to transvaginal ultrasound, completed approximately 6-8 weeks postpartum

Secondary outcomes

  1. Distance of cesarean scar niche from internal os

    Sonographic distance of cesarean scar niche from internal cervical os, measured in millimeters, on postpartum transvaginal ultrasound. The investigator team hypothesizes that a scar further from the internal os has increased risk for abnormal placentation in future pregnancies.

    Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum

  2. Size of cesarean scar niche

    Sonographic dimensions of length and width of cesarean scar niche, measured in mm, on transvaginal ultrasound. The investigator team hypothesizes that larger niches are associated with increased risk of abnormal placentation in future pregnancies and increased risk of future gynecologic complaints.

    Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum

  3. Measurement of residual myometrium

    Sonographic measurement of residual myometrium in mm by transvaginal ultrasound. Thinner residual myometrium may imply a larger defect, increased risk for abnormal placentation or formation of a uterine window in future pregnancies.

    Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum

  4. Size of cesarean scar defect in subsequent pregnancy

    Sonographic measurement of dimensions (length and width) of cesarean scar defect in subsequent pregnancy, measured in mm, to assess if larger postpartum niches are associated with larger defects in subsequent pregnancies as they may carry increased risk of morbidity in the pregnancy.

    Time frame: From time of enrollment to time of subsequent pregnancy, up to 5 years following baseline pregnancy

  5. Cases of abnormal placentation in subsequent pregnancies

    If encountered in a subsequent pregnancy, the number of cases of abnormal placentation in the cesarean scar and placenta accreta spectrum will be summarized. Ultrasound evidence of placenta accreta spectrum include disappearance of the border between placenta and myometrium, placental lacunae, increased vasculature from placenta extending into myometrium, abnormal invasion of placenta into surrounding organs and structures. Pathology will be used to confirm the number of cases of placenta accreta spectrum.

    Time frame: From time of enrollment to time of subsequent pregnancy, up to 5 years following baseline pregnancy

  6. Uterine Position/Flexion

    As an anteverted and retroflexed uterus is commonly the result of a cesarean delivery and scar tissue altering anatomical position, the clinicians will observe if a bladder flap alters position of the uterus. At the 6 week transvaginal ultrasound, the position of the uterus as anteverted or retroverted and flexion as anteflexed or retroflexed will be recorded. In the sagittal plane on transvaginal ultrasound, if the cervix appears on the viewer's right or left, the position is anteverted or retroverted, respectively. The anterior or posterior flexion of the fundus will define anteflexion and retroflexion, respectively

    Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum

  7. Number/percentage of Operative and Postoperative Complications

    Patient charts will be reviewed to summarize the number/percentage of surgical complications in each arm. This includes complications such as damage to surrounding structures, hemorrhage, hematoma formation, surgical site infections.

    Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum

07

Study locations

2 of 2 sites recruiting
  • Jack D. Weiler Hospital - Einstein Campus
    The Bronx, New York 10461, United States
    Recruiting
  • Montefiore Einstein Hospital - Wakefield Campus
    The Bronx, New York 10466, United States
    Recruiting
08

References and documents

Publications

  • Kamel R, Thilaganathan B. Time to reconsider elective Cesarean birth. Ultrasound Obstet Gynecol. 2021 Mar;57(3):363-365. doi: 10.1002/uog.22158. No abstract available. PubMed 33220003 ↗
  • Kamara M, Henderson JJ, Doherty DA, Dickinson JE, Pennell CE. The risk of placenta accreta following primary elective caesarean delivery: a case-control study. BJOG. 2013 Jun;120(7):879-86. doi: 10.1111/1471-0528.12148. Epub 2013 Feb 28. PubMed 23448347 ↗
  • Shi XM, Wang Y, Zhang Y, Wei Y, Chen L, Zhao YY. Effect of Primary Elective Cesarean Delivery on Placenta Accreta: A Case-Control Study. Chin Med J (Engl). 2018 Mar 20;131(6):672-676. doi: 10.4103/0366-6999.226902. PubMed 29521289 ↗
  • O'Neill HA, Egan G, Walsh CA, Cotter AM, Walsh SR. Omission of the bladder flap at caesarean section reduces delivery time without increased morbidity: a meta-analysis of randomised controlled trials. Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:20-6. doi: 10.1016/j.ejogrb.2013.12.020. Epub 2013 Dec 22. PubMed 24411951 ↗
  • Tuuli MG, Odibo AO, Fogertey P, Roehl K, Stamilio D, Macones GA. Utility of the bladder flap at cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2012 Apr;119(4):815-21. doi: 10.1097/AOG.0b013e31824c0e12. PubMed 22395144 ↗
  • Fukuda M, Fukuda K, Shimizu T, Bujold E. Ultrasound Assessment of Lower Uterine Segment Thickness During Pregnancy, Labour, and the Postpartum Period. J Obstet Gynaecol Can. 2016 Feb;38(2):134-40. doi: 10.1016/j.jogc.2015.12.009. Epub 2016 Mar 2. PubMed 27032737 ↗
  • Rorie DK, Newton M. Histologic and chemical studies of the smooth muscle in the human cervix and uterus. Am J Obstet Gynecol. 1967 Oct 15;99(4):466-9. doi: 10.1016/0002-9378(67)90292-x. PubMed 4167498 ↗
  • Kamel R, Eissa T, Sharaf M, Negm S, Thilaganathan B. Position and integrity of uterine scar are determined by degree of cervical dilatation at time of Cesarean section. Ultrasound Obstet Gynecol. 2021 Mar;57(3):466-470. doi: 10.1002/uog.22053. PubMed 32330331 ↗
  • Klein Meuleman SJM, Min N, Hehenkamp WJK, Post Uiterweer ED, Huirne JAF, de Leeuw RA. The definition, diagnosis, and symptoms of the uterine niche - A systematic review. Best Pract Res Clin Obstet Gynaecol. 2023 Aug;90:102390. doi: 10.1016/j.bpobgyn.2023.102390. Epub 2023 Jul 15. PubMed 37506497 ↗
  • Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018 Jan;218(1):75-87. doi: 10.1016/j.ajog.2017.05.067. Epub 2017 Jun 24. PubMed 28599899 ↗
  • Angolile CM, Max BL, Mushemba J, Mashauri HL. Global increased cesarean section rates and public health implications: A call to action. Health Sci Rep. 2023 May 18;6(5):e1274. doi: 10.1002/hsr2.1274. eCollection 2023 May. PubMed 37216058 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in future publications will be made available to qualified researchers upon request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 6 months after trial publication for a period of up to 5 years.

Access criteria: Requests will require a data use agreement and a proposal review by the study team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.

Of 175 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 10 months is below that.

Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 9, 2026
StartActual
Oct 3, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Aug 1, 2032
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Oct 3, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Oct 15, 2026→Oct 3, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07634679
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Oct 3, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Oct 7, 2026

Study contacts

Alyssa Yeung, MD
Contact
ayeung@montefiore.org
574-329-8771
Pe'er Dar, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion